Literature DB >> 16395717

Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo.

Gourapura J Renukaradhya1, Venkataraman Sriram, Wenjun Du, Jacquelyn Gervay-Hague, Luc Van Kaer, Randy R Brutkiewicz.   

Abstract

We have investigated the role of the host's CD1d-dependent innate antitumor immune response in a murine T-cell lymphoma model in vivo. We found that C57BL/6 wildtype (WT) mice inoculated with RMA/S cells transfected with murine CD1d1 died at the same rate as mice inoculated with vector-transfected cells. In contrast, natural killer T (NKT) cell-deficient CD1d or Jalpha18 knockout mice inoculated with CD1d-transfected RMA/S cells survived significantly longer than mice inoculated with vector-transfected RMA/S cells, implicating the involvement of invariant NKT (iNKT) cells in inhibiting antitumor activity in vivo. In contrast to the mutant mice, which produced more of the proinflammatory cytokines IFN-gamma and GM-CSF, WT mice produced significantly elevated amounts of IL-13. Antitumor activity in the knockout mice was not due to the development of CD1d-specific cytotoxic T lymphocytes or circulating antibodies. However, iNKT cell numbers were elevated in tumor-bearing mice. Thus, iNKT cells may be playing a negative role in the host's antitumor immune response against T-cell lymphomas in a CD1d-dependent manner. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395717     DOI: 10.1002/ijc.21764

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

Review 2.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

3.  iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo .

Authors:  Hamid Bassiri; Rupali Das; Peng Guan; David M Barrett; Patrick J Brennan; Pinaki P Banerjee; Susan J Wiener; Jordan S Orange; Michael B Brenner; Stephan A Grupp; Kim E Nichols
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

Review 4.  The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Cancer Immunol Immunother       Date:  2014-01-03       Impact factor: 6.968

5.  Type I natural killer T cells suppress tumors caused by p53 loss in mice.

Authors:  Jeremy B Swann; Adam P Uldrich; Serani van Dommelen; Janelle Sharkey; William K Murray; Dale I Godfrey; Mark J Smyth
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

6.  CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b+ T cell lymphoma.

Authors:  Sreya Bagchi; Sha Li; Chyung-Ru Wang
Journal:  Oncoimmunology       Date:  2016-07-22       Impact factor: 8.110

Review 7.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.

Authors:  Gourapura J Renukaradhya; Masood A Khan; Marcus Vieira; Wenjun Du; Jacquelyn Gervay-Hague; Randy R Brutkiewicz
Journal:  Blood       Date:  2008-04-16       Impact factor: 22.113

Review 9.  The contrasting roles of NKT cells in tumor immunity.

Authors:  Jay A Berzofsky; Masaki Terabe
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

10.  Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.

Authors:  Rachel D Kuns; Edward S Morris; Kelli P A Macdonald; Kate A Markey; Helen M Morris; Neil C Raffelt; Tatjana Banovic; Alistair L J Don; Vanessa Rowe; Angela C Burman; Andrew D Clouston; Camile Farah; Gurdyal S Besra; Petr A Illarionov; Mark J Smyth; Steven A Porcelli; Geoffrey R Hill
Journal:  Blood       Date:  2009-04-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.